Company news

Niagen Bioscience, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

October 20, 2025

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

October 5, 2025

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide

September 30, 2025

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+

September 16, 2025

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

August 6, 2025

Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference

August 3, 2025

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

July 22, 2025

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

July 13, 2025

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

July 7, 2025

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

June 19, 2025

Niagen Bioscience to Participate in the BIO 2025 International Convention

June 10, 2025

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

June 8, 2025

Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference

June 3, 2025

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

May 6, 2025

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

May 4, 2025

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

April 28, 2025

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

April 27, 2025

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

April 6, 2025

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

March 19, 2025

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science

March 19, 2025

ChromaDex to Present at the 37th Annual Roth Conference

March 10, 2025

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

March 3, 2025

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

February 24, 2025

ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

January 5, 2025

ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

December 2, 2024

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

November 6, 2024

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

October 30, 2024

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

October 23, 2024

ChromaDex to Participate in the 17th Annual LD Micro Main Event

October 22, 2024

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

September 25, 2024

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

September 19, 2024

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics

September 9, 2024

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024

August 22, 2024

ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+

August 18, 2024

ChromaDex Corporation Reports Second Quarter 2024 Financial Results

August 6, 2024

ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference

August 4, 2024

ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

July 23, 2024

ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)

July 22, 2024

ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel

July 21, 2024

ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August

July 15, 2024

ChromaDex to Join Russell 2000® Index

June 30, 2024

Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)

June 23, 2024

ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)

June 12, 2024

ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)

June 6, 2024

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024

June 3, 2024

ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 22, 2024

ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award

May 21, 2024

ChromaDex Corporation Reports First Quarter 2024 Financial Results

May 7, 2024

ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement

April 29, 2024

ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®

April 24, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 30 calls. Every call is listed under its year.

Decks

The 5 newest of 59 decks. Every deck is listed under its year.